Alzheimer's Disease International (ADI)
News, blogs and stories from across the field of dementia, the work of Alzheimer’s Disease International and our members.
After two years of dedicated and persistent advocacy by ADI, dementia will, for the first time, be formally recognised within the new UN Political Declaration on noncommunicable diseases (NCDs) and mental health, as a leading NCD.
The 78th World Health Assembly has been a whirlwind week for ADI as, after 18-months of advocacy, the World Health Assembly has agreed to extend the Global Action Plan on the Public Health Response to Dementia by 6-years, to 2031.
The World Alzheimer Report 2020 has been awarded the European Healthcare Design (EHD) 2021 Award for Outstanding Contribution to Global Knowledge.
Aduhelm (aducanumab) is the first new dementia drug treatment to come to market since 2003.
Third year university students in Bandar Seri Begawan, Brunei Drussalam reflect on their community experience with ADI member demensia Brunei (dB).
ADI members in the European and Caribbean regions took part in the first regional meetings of 2021 and since the COVID-19 pandemic began in early 2020.
As the 74th World Health Assembly begins, ADI is sharing a statement submitted to the World Health Organization (WHO) and Member States.
Davos Alzheimer's Collaborative (DAC) Co-chairs, Arnaud Bernaert and George Vradenburg, write about how DAC is building a coalition in order to accelerate Alzheimer's and dementia innovation.
ADI is pleased to welcome 6 new member associations, as well as new members to the ADI board.
During the 60-minute meeting, the advisory panel discussed ADI's activities over the last year, as well as proposals for future avenues of research, including a working group to explore the impact of COVID-19 as a potential risk factor for accelerating dementia.